Chinese Biotechnology Services (08037) subsidiary will present the phase I clinical trial results of LY007 cell injection solution at the 18th International Malignant Lymphoma Conference and the 30th European Hematology Association Annual Meeting.

- Wisdom Finance APP News, China Biotech Services (08037) announced that, following the display of clinical trial results in the United States last year, the company's indirectly non-wholly-owned subsidiary, Shanghai Longyao Biotechnology Co., Ltd. (Shanghai Longyao), will be holding the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland from June 17, 2025 to June 21, 2025, as well as the 30th European Hematology Association (EHA) Annual Meeting in Milan, Italy from June 12, 2025 to June 15, 2025. At the events, they will present the Phase I clinical trial results of the LY007 cell injection in poster form.